Moving closer to MU Stage 3

Laura Pedulli | | Health Exec | Digital Transformation

 

Big news on the Meaningful Use Stage 3 front: The proposed rule has been sent to the Office of Management and Budget and will be published in the Federal Register upon review, reports Clinical Innovation + Technology.

“We are proposing the Stage 3 criteria that eligible professionals, eligible hospitals and access hospitals must meet in order to successfully demonstrate Meaningful Use under the Medicare and Medicaid EHR Incentive Programs, focusing on advanced use of EHR technology to promote improved outcomes for patients,” states the Department of Health and Human Services in their submission to OMB. “Stage 3 will also propose changes to the reporting period, timelines and structure of the program, including providing a single definition of Meaningful Use. These changes will provide a flexible, yet, clearer framework to ensure future sustainability of the EHR program and reduce confusion stemming from multiple stage requirements.”

Read more below:

Stage 3 proposed rule on the way

Laura Pedulli

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.